Patient Tumor Matrix Shifts Ovarian Organoid Growth and Chemotherapy Response
Ovarian cancer organoids grown in corresponding patient-derived decellularized matrix grew more slowly and had higher fitted chemotherapy IC50 values than conventional cultures. The comparison identifies a matrix-dependent response without establishing drug-penetration mechanisms or clinical prediction.
Keeping Patient Matrix as a Culture Component
Extracellular matrix can alter a tumor culture through structure, mechanics and molecular signals. A Translational Oncology study from the University of Padua and collaborating academic centers used decellularized high-grade serous ovarian carcinoma tissue as a support for patient-derived organoids. It compared this setting with conventional Geltrex culture to examine growth and chemotherapy response.
The tissue collection included tumor and omental material, with paired specimens for some comparisons. Decellularization reduced DNA by approximately 98% in tumor tissue and 95% in omentum. Collagen I and IV, laminin and glycosaminoglycans remained, as did aspects of collagen orientation. Porosity did not change significantly, although protein abundance did: the proteomic comparison found hundreds of increased or decreased proteins. The processed matrix retained important features without remaining molecularly identical to the original tissue.
Organoids Preserved Some Features and Showed Patient Variation
Morphological characterization covered fifteen organoid lines from fifteen patients. Ten formed dense structures, three were less cohesive and two were cystic. CK7 and p16 staining agreed with source tissue in all examined comparisons, while p53, PAX8 and WT1 concordance was approximately 66%. The cultures therefore retained several diagnostic features with incomplete agreement for others.
Expression analysis in nine models found heterogeneous epithelial–mesenchymal-transition-related profiles. This variation is relevant to interpreting a matrix experiment: the same support material need not act identically on cultures with different starting states. The study did not identify a single expression profile shared by every organoid.
Growth in the Matrix Was Spatially Uneven
The investigators introduced organoids into their corresponding patient tumor matrix and followed the recellularized constructs for up to 21 days. Cells remained viable and grew within the structure. Ki67 positivity was 81.7% ± 2.6% near the margin, compared with 42.5% ± 4.7% across the whole construct, indicating a nonuniform distribution of proliferation. The Ki67 values are means ± standard error (SE).
A paired growth comparison used four organoid models. Growth was similar in Geltrex and patient matrix during the first six days, after which the Geltrex cultures grew faster. The patient-derived support therefore changed the growth trajectory as well as the spatial pattern, both of which can affect how a later viability assay is interpreted.
The Matrix Setting Raised Fitted IC50 Values
Drug testing used six conventional PDO models and five recellularized matrix models. Ten-day conventional PDO cultures received paclitaxel or an equal-ratio paclitaxel–carboplatin combination at nominal concentrations of 1, 10, 100 or 1,000 μM for 72 hours. Matrix constructs were challenged at the corresponding PDO-derived IC50. Resazurin fluorescence measured metabolic activity. The paper separately reports fitted IC50 values for both culture settings, while the main Methods does not specify a matching full concentration series for the matrix constructs.
The fitted paclitaxel IC50 was 37.10 μM in conventional PDO culture and 58.8 μM in the matrix setting. For the combination, the corresponding values were 6.8 and 27.1 μM. Applying the conventional-culture IC50 to the matrix construct left its metabolic signal above half the untreated level. Under these assay conditions, the patient-derived matrix was associated with reduced apparent drug sensitivity.
The Response Shift Does Not Identify One Mechanism
Drug transport, matrix signaling, slower growth and local oxygen conditions could each contribute to the difference. The study did not directly measure drug penetration as the cause, and a resazurin endpoint combines survival with metabolic activity. The constructs also lacked living stromal and immune components, while patient tissue composition introduces another source of variability.
The work shows that changing the culture support can shift an ovarian organoid chemotherapy result. It does not establish a clinically accurate dose or demonstrate correspondence with paired patient outcomes. Its immediate application is comparative: matrix background, growth kinetics and assay endpoint need to be considered together when interpreting an organoid drug-response curve.